Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Artificial Intelligence

Aigenpulse introduces novel data intelligence platform to life science markets

   by Alice Chamberlain    20

Life science and data technology innovator, Aigenpulse, is introducing a new state of-the-art data intelligence platform which is designed to expedite the drug discovery and development process. The Aigenpulse platform harnesses the latest artificial intelligence and machine learning tools to deliver advanced analytics to underpin scientific decision making.

Major VC Rounds For AI-driven Biotechs in 2020

   by Andrii Buvailo    351
Major VC Rounds For AI-driven Biotechs in 2020

The ongoing COVID19 crisis forced biotech-oriented venture capitalists (VC) to somewhat slow down the pace of their usual deal-flow -- according to data by PitchBook biopharma venture deals in 2020 are down roughly 16% compared to last year. 

However, there is still a lot going on in drug discovery and healthcare, and here I would like to specifically focus on artificial intelligence (AI)-driven biotech and health tech startups who managed to raise notable rounds in 2020, so far (based on our report “A Landscape of Artificial Intelligence (AI) In Drug Discovery and Development”). The deals are ordered by the amount of money raised 

OKRA smashes target of 2 million validated predictions for big Pharma, 6 months early

   by Marina Gonzalo    126
OKRA smashes target of 2 million validated predictions for big Pharma, 6 months early

Cambridge, UK, 19 June 2020 - OKRA, a leading provider of Artificial Intelligence (AI) driven analytics for Life Sciences, today hit an important milestone, delivering 2 million validated predictions so far in 2020, smashing through its yearly target in just half the expected time. This underscores OKRA’s achievements in empowering the pharmaceutical industry with explainable, real-time AI solutions.

Virtual Immunostaining for Digital Pathology

   by Victor Dillard    496
Virtual Immunostaining for Digital Pathology

Owkin is a French-American startup, backed by Google Ventures among others, that deploys Artificial Intelligence (AI) and Federated Learning for medical research. The company was co-founded in 2016 by Thomas Clozel, a hematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher at the École Normale Supérieure, and a Stanford University PostDoc.

Over the years, the team at Owkin has developed AI systems to analyze and interpret multimodal medical data, including pathology images, radiology images, genetic data, lab analysis, and clinical outcomes. The company recently announced the launch of a new product -- Virtual Staining, integrated as a feature in Owkin Studio platform.